36 citations
,
August 2021 in “Nature Cell Biology” Organoids can help study COVID-19 and develop treatments, but face challenges like instability and limited renewal.
4 citations
,
May 2021 in “Lasers in Surgery and Medicine” Light therapy reduces scalp inflammation, boosts hair regrowth with Minoxidil 2%.
September 2024 in “Pigment International” Vitiligo is now seen as a systemic disease with promising new treatments and may offer protection against some diseases.
123 citations
,
January 2012 in “The Keio Journal of Medicine” Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
January 2019 in “Elsevier eBooks” Different hair disorders have specific treatments and outcomes, with some resolving on their own and others requiring medication or emotional support.
19 citations
,
July 2022 in “PNAS Nexus” Similar treatments might work for different types of scarring hair loss.
4 citations
,
April 2019 in “Cell Stem Cell” Certain immune cells in the skin can stop hair from growing.
4 citations
,
November 2024 in “Cell Biology and Toxicology” Blocking certain receptors in the lungs might help treat a specific type of asthma.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
23 citations
,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
23 citations
,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
1 citations
,
June 2023 in “Cells” Exosomes could be a promising way to help repair skin and treat skin disorders.
170 citations
,
September 2020 in “Viruses” Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.
2 citations
,
March 2024 in “PubMed” More research is needed on alopecia areata treatments and its psychological effects.
60 citations
,
November 2023 in “Biology” Aging skin causes inflammation that affects the whole body.
29 citations
,
January 2023 in “Journal of Clinical Medicine” Psychological interventions can improve mental health and quality of life in people with alopecia.
November 2025 in “Cosmetics” Most trichological shampoo ingredients lack strong evidence for effectiveness against hair loss.
June 2025 in “Dermatopathology” Dupilumab and COVID-19 can worsen or trigger psoriasis.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
January 2024 in “Biomedicines” The review shows that skin symptoms like chronic fungal infections, hair loss, and skin depigmentation are key for early detection and management of APECED.
2 citations
,
December 2025 in “Cosmetics” Proper scalp care can improve hair health and delay ageing signs.
Polydopamine is promising for personalized medicine and biomedical technology due to its strong adhesion and biocompatibility.
April 2018 in “Journal of Investigative Dermatology” Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.